&nbsp;

Nov 2024

Drug

pegylated liposomal DOXOrubicin

Other Name(s): Caelyx®

Quick Link(s):

Sep 2025

Drug

bendamustine

Other Name(s): Treanda®

Quick Link(s):

Nov 2024

Drug

PERTuzumab

Other Name(s): Perjeta®

Quick Link(s):

Sep 2022

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Jun 2025

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Sep 2025

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Nov 2025

Regimen

BMP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

Regimen

BORT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

PGLDX

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PGLDX

Cancer Type:

Sarcoma,

Kaposi's Sarcoma

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer

Drugs Used:

PANitumumab